Page 114 - CombinedTest_Neat

Site Performance Summary:

Tiffin's Supply Expense was over budget by $20K.
Med/Surg showing low spend at only 66% of budget due to Admissions and
Total Patient Days both being 8% below budget. Total Surgery volume was
also 6% below budget.
Unfavorable spend can be attributed to Drugs ($25K), Lab ($28K) and Non-
CRM Implants ($17K).

Despite a lower-volume and lower-performing month, Net Revenue was
favorable.

Key Challenges: 2-3 key contributors for each expense subaccount
Low admissions and total patient days attributed to minimal spend in
Med/Surg.

Tiffin Leader's Summary
Med/Surg

Drug spend was unfavorable due to high-dollar usage from Oncology,
specifically from Keytruda and Avastin, as well as high spend in blood form,
coag and thrombosis drug subaccount as a number of these drugs are ordered
for chemo patients requiring red/white blood cell booster. Cold and Flu
Rx season attributable to excess spend on Anti-infective drugs.

Knees/Hips volume did decrease from PY; however, increased inpatient
surgeries and Genito-Urinary procedures accounted for excess spend.

Implants

Lab - $20K Payment to the College of American Pathologists to cover for
2018 Surveys.

Other Expenses

Actions Taken/Planned:
Volume Data
Alt Sourcing
Capital Avoidance